Cost-Utility Analysis of Cataract Surgery in Advanced Glaucoma Patients

被引:7
|
作者
Xu, Xian [1 ,2 ]
Ma, Ying-Yan [1 ,2 ]
Zou, Hai-Dong [1 ,2 ]
机构
[1] Shanghai Eye Hosp, Shanghai Eye Dis Prevent & Treatment Ctr, 380 Kangding Rd, Shanghai 200040, Peoples R China
[2] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Ophthalmol, Shanghai, Peoples R China
关键词
advanced glaucoma; cataract surgery; time trade-off (TTO) method; quality-adjusted life-years (QALYs); incremental cost-effectiveness ratio (ICER);
D O I
10.1097/IJG.0000000000000313
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To assess the cost-effectiveness of cataract surgery in advanced glaucoma (AG) patients. Materials and Methods: A total of 93 patients with AG who underwent cataract surgeries were collected prospectively from June 2010 through June 2013 in Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai, and were followed up for at least 3 months. A standard phacoemulsification technique was used to remove cataract(s). No complications occurred intraoperatively or postoperatively. Costs associated with surgery were recorded. Utility values of cataract surgery were obtained by using time trade-off method. Quality-adjusted life-years (QALYs) were calculated using the patients' life expectancy at a 3% discounted rate. Incremental cost-utility analysis was performed (compared with no treatment) by calculating the incremental cost-effectiveness ratio (ICER), that is, the mean incremental cost for each QALY. The bootstrap method was used for statistical analysis, and sensitivity analyses were performed to test robustness of the results. Results: The mean incremental cost of cataract surgery was 9876 Chinese yuan (CNY) [1593 US dollar (USD)] [95% confidence interval (CI), 9144-10,570CNY (1475-1705 USD)]. The mean additional QALYs gained were 2.20 (95% CI, 1.85-2.54), and the incremental cost for each additional QALY was 4508CNY (727 USD) [95% CI, 3890-5234CNY (627-844 USD)], far lower than the per capita annual disposable income in Shanghai, 40,188CNY (6482 USD). Conclusion: For AG patients, cataract surgery does help obtain more QALYs and was highly cost effective.
引用
收藏
页码:E657 / E662
页数:6
相关论文
共 50 条
  • [31] Liver Resection for Advanced Intrahepatic Cholangiocarcinoma: A Cost-Utility Analysis
    Umberto Cillo
    Gaya Spolverato
    Alessandro Vitale
    Aslam Ejaz
    Sara Lonardi
    David Cosgrove
    Timothy M. Pawlik
    World Journal of Surgery, 2015, 39 : 2500 - 2509
  • [32] Liver Resection for Advanced Intrahepatic Cholangiocarcinoma: A Cost-Utility Analysis
    Cillo, Umberto
    Spolverato, Gaya
    Vitale, Alessandro
    Ejaz, Aslam
    Lonardi, Sara
    Cosgrove, David
    Pawlik, Timothy M.
    WORLD JOURNAL OF SURGERY, 2015, 39 (10) : 2500 - 2509
  • [33] Cost-utility analyses in orthopaedic surgery
    Brauer, CA
    Rosen, AB
    Olchanski, NV
    Neumann, PJ
    JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2005, 87A (06): : 1253 - 1259
  • [34] Shunt surgery in iNPH patients is cost-effective – a cost-utility analysis in the Western Sweden setting
    Mats Tullberg
    Jakob Petersen
    Josefine Persson
    Daniel Jaraj
    Kerstin Andrén
    Per Hellström
    Carsten Wikkelsö
    Åsa Lundgren-Nilsson
    Fluids and Barriers of the CNS, 12 (Suppl 1)
  • [35] COST-UTILITY ANALYSIS IN UROLOGY
    Fero, Katherine
    Sharma, Vidit
    Lec, Patrick
    Saigal, Christopher
    Chamie, Karim
    JOURNAL OF UROLOGY, 2021, 206 : E435 - E436
  • [36] Cost-utility analysis for UTIs
    Schaefer, SE
    JOURNAL OF FAMILY PRACTICE, 1997, 44 (04): : 329 - 329
  • [37] Cost-utility analysis in schizophrenia
    Awad, AG
    Voruganti, LP
    JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 : 22 - 28
  • [38] Cost-utility analysis - Response
    Neumann, PJ
    Chapman, RH
    Stone, PW
    ANNALS OF INTERNAL MEDICINE, 2001, 134 (07) : 626 - 626
  • [39] Cost-utility analysis and otolaryngology
    Hamilton, D.
    Hulme, C.
    Flood, L.
    Powell, S.
    JOURNAL OF LARYNGOLOGY AND OTOLOGY, 2014, 128 (02): : 112 - 118
  • [40] Cost-utility analysis of evolocumab in patients with ASCVD in Italy
    Marcellusi, Andrea
    Bini, Chiara
    Rotundo, Maria Assunta
    Arcangeli, Emanuela
    Martinez, Laura
    Vilela, Francesc Sorio
    Mennini, Francesco Saverio
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2021, 8 : 155 - 167